Disruption of amyloid β-protein processing drives Alzheimer’s

Professor Michael S. Wolfe explored the issue whereby increased concentrations of this form of Aβ proteins does not always occur with disease-causing mutations, suggesting a different step in Aβ processing could be triggering Alzheimer’s

In the study of familial Alzheimer’s disease, a specific form of amyloid β-protein (Aβ) found in amyloid plaques has been the focus of many investigations as a key driver of disease. However, increased concentrations of this form of Aβ does not always occur with disease-causing mutations, suggesting a different step in Aβ processing could be triggering Alzheimer’s. Professor Michael S. […]

Read More… from Disruption of amyloid β-protein processing drives Alzheimer’s

The trials and tribulations in the drug discovery cycle: A particular case for Alzheimer’s disease

The trials and tribulations in the drug discovery cycle

As people live longer lives, the spectre of Alzheimer’s disease will only grow. Scientists now know that the amyloid beta (Aβ) peptides are important for treating Alzheimer’s, particularly Aβ42 which aggregates into the amyloid plaques that trigger the disease. Researchers have been looking to target γ-secretase – the enzyme that creates pathogenic Aβ42 affecting the relative abundance of short Aβ […]

Read More… from The trials and tribulations in the drug discovery cycle: A particular case for Alzheimer’s disease